Acadia Pharmaceuticals (ACAD) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Acadia Pharmaceuticals (NASDAQ:ACAD) in a research report report published on Wednesday.

Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Acadia Pharmaceuticals from a sell rating to a buy rating and set a $18.00 price objective on the stock in a research note on Tuesday, May 1st. BidaskClub raised shares of Acadia Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday. JPMorgan Chase set a $50.00 price objective on shares of Acadia Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, April 10th. Finally, ValuEngine lowered shares of Acadia Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, March 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $48.50.

NASDAQ ACAD traded down $0.13 on Wednesday, hitting $18.00. 1,792,106 shares of the company were exchanged, compared to its average volume of 3,806,521. The firm has a market cap of $2.26 billion, a PE ratio of -7.63 and a beta of 3.37. Acadia Pharmaceuticals has a 12 month low of $14.51 and a 12 month high of $41.20.

Acadia Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.12. Acadia Pharmaceuticals had a negative net margin of 161.44% and a negative return on equity of 71.47%. The firm had revenue of $48.90 million for the quarter, compared to analyst estimates of $47.06 million. During the same period last year, the firm earned ($0.72) earnings per share. The business’s quarterly revenue was up 219.6% compared to the same quarter last year. equities analysts anticipate that Acadia Pharmaceuticals will post -1.71 EPS for the current year.

In other news, Director Daniel B. Soland bought 7,000 shares of the stock in a transaction dated Thursday, March 1st. The stock was bought at an average price of $23.91 per share, for a total transaction of $167,370.00. Following the completion of the acquisition, the director now directly owns 2,000 shares in the company, valued at approximately $47,820. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 22.25% of the company’s stock.

Several hedge funds have recently made changes to their positions in ACAD. Point72 Asia Hong Kong Ltd raised its holdings in shares of Acadia Pharmaceuticals by 822.9% in the first quarter. Point72 Asia Hong Kong Ltd now owns 4,439 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 3,958 shares during the last quarter. Earnest Partners LLC purchased a new stake in shares of Acadia Pharmaceuticals in the fourth quarter valued at about $133,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Acadia Pharmaceuticals in the fourth quarter valued at about $200,000. State of Alaska Department of Revenue purchased a new stake in shares of Acadia Pharmaceuticals in the fourth quarter valued at about $219,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Acadia Pharmaceuticals by 30.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,403 shares of the biopharmaceutical company’s stock valued at $223,000 after purchasing an additional 1,733 shares during the last quarter. Institutional investors own 95.54% of the company’s stock.

Acadia Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Analyst Recommendations for Acadia Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for Acadia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply